Key Points: Serotonin receptor antagonists reduce the incidence of AKI in patients receiving cisplatin as chemotherapy. New-generation serotonin receptors do not offer any additional advantage in terms of protection from cisplatin induced AKI.
Background: Cisplatin is an effective first-line therapy for a variety of cancers.